ClinicalTrials.gg
RecruitingNCT05811624BO2WLUpdated Aug 20, 2026

Lifestyle Intervention in Overweight/Obese Chronic Low Back Pain (CLBP) Patients: an International Multi-center RCT

An interventional study of Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy. and Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone. in Overweight or Obesity and Chronic Low-back Pain, sponsored by Vrije Universiteit Brussel. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Vrije Universiteit Brussel · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Obesity with a site in Belgium — 40 open to participants now, 56 under way, 22 of them phase 3. Obesity · Belgium.

Planned enrollment
44th of 97
252 · median 200
Started
2023
with 9 others
No phase
36 of 133
7 open now
Primary completion
2028-04
later than 32 of 55 live
Registered
94th of 133
by date

Among the 133 studies in Obesity with a site in Belgium, this one is the 44th largest by planned enrollment of the 97 interventional ones that give a count, is one of 10 that started in 2023, is one of 36 with no phase, reaches primary completion later than 32 of the 55 other live ones, and was the 94th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

40 of the 133 studies in Obesity with a site in Belgium are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Obesity with a site in Belgium, or all of them as a file.
02

Study summary

Chronic low back pain (CLBP) is the most expensive cause of workrelated disability: it causes the highest number of years lived with disability. The most severe and debilitated CLBP patients often have comorbidities such as overweight and obesity. Despite the growing body of scientific literature pointing towards the close interaction between overweight/obesity and CLBP, few treatment programs for people with CLBP nowadays take overweight into account. Therefore this study will examine the added value of a behavioral weight reduction program (changes in diet, behavior and physical exercise) to current best evidence rehabilitation (pain neuroscience education plus cognition-targeted exercise therapy) for overweight or obese people with CLBP. An international, multicenter randomized controlled trial comparing a behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy versus pain neuroscience education and cognition-targeted exercise therapy alone, will be conducted. The primary outcome is pain and the primary endpoint was chosen at 12 months follow-up; secondary outcomes include health care use and daily functioning (see detailed description of outcomes for an overview of all secondary outcomes). If the promising results of the proof of concept study are corroborated, the new intervention will have a high socio-economic impact, including an annual health care cost reduction of €66 million in Switzerland, and €60 million in Flanders, and is expected to increase life expectancy in the long term.

Read the detailed description

Rationale:

Chronic low back pain (CLBP) is the most common and important clinical, social, economic, and public health problem of all chronic pain disorders across the world. In addition to its high prevalence, CLBP is a severely disabling disorder characterized by tremendous personal and socioeconomic impact. Furthermore, it is the most common cause of work-related disability, generating long-term sick-leaves, and it causes the highest number of years lived with disability.

The most severe and debilitated CLBP patients often have comorbidities such as overweight and obesity. In fact, pain intensity and disability in people with CLBP show dose-responses to body mass index (BMI), waist circumference, percent fat and fat mass. Ample studies and several meta-analyses indeed confirm that overweight and obesity are associated with LBP, with overweight and obesity even being a risk factors for low back pain. Regarding socio-economic impact, overweight or obesity is not only related to LBP persistence, but also to higher rates of health care seeking for LBP. Obviously, people with CLBP who are overweight or obese, are likely to have more complex health needs requiring focus on lifestyle behavioral factors such as physical activity/exercise and diet.

CLBP is a complex disorder which is difficult to treat. Exercise therapy is an evidence-based treatment for CLBP both general exercises and cognition-targeted exercise therapy have shown beneficial effects on pain in patients with CLBP. Unfortunately, current treatments for CLBP apply a 'one-size-fits-all' approach and do not address comorbidities like obesity. This knowledge gap is now acknowledged internationally: overweight and obesity are increasingly recognized as a plausible therapeutic target for people with CLBP. Despite the growing body of scientific literature pointing towards the close interaction between overweight/obesity and CLBP few treatment programs for people with CLBP nowadays take overweight into account.

Few studies explored the added value of weight reduction to the management of people with CLBP. Yet, proof of concept for combining dietary changes with exercise therapy for patients with CLBP and comorbid overweight/obesity show promising results. Here we propose studying the added value of a behavioral weight reduction program (changes in diet, behavior, and physical exercise) to blended rehabilitation (PNE plus CTET) for overweight or obese people with CLBP. Both treatments are effective in their specific target population (i.e., behavioral weight reduction for overweight/obese people and PNE plus CTET for people with CLBP and normal BMI), but whether their combined approach is cumulative in overweight/obese people with CLBP is currently unknown and represents an important research priority.

Objectives:

The primary objective is to examine if a behavioral weight reduction program combined with Pain Neuroscience Education (PNE) and Cognition-Targeted Exercise Therapy (CTET) is superior to reduce pain at 12 months follow-up compared PNE and CTET alone, in overweight or obese people with CLBP.

Secondary objectives are to examine the effects of adding a behavioral weight reduction program combined with PNE and CTET, compared to PNE and CTET alone, on 1) other pain related outcomes (pain interference, pain distribution and pain beliefs), 2) on anthropometrics (body weight/composition, muscle thickness and fat distribution), 3) on energy balance related behavior (24h continuous activity monitoring, dietary intake and sleep) and finally 4) on health economics (heath care utilization, productivity loss and quality of life) at 12 months follow-up.

Interventions:

Both interventions (experimental and control) are organized equally: all participants will receive 18 treatment sessions over a 14-week period see table 2 for a detailed overview. Rather than practical, treatment arms will differ in content.

The control intervention will consist of a total of 18 treatment sessions distributed over 14 weeks. It comprises of only the chronic-pain-focused interventions: 3 sessions of PNE in the first 2 weeks \& secondly, 15 sessions of CTET in the remaining 12 weeks.

The experimental intervention will consist of a total of 18 treatment sessions distributed over 14 weeks. The first part will consist of chronic-pain-focused interventions: firstly, 3 sessions of PNE in the first 2 weeks \& secondly, 15 sessions of CTET in the remaining 12 weeks. The second part will consist of a more weight-reduction-focused intervention. The weight reduction intervention is a lifestyle approach that will be integrated in the CTET intervention, implying that grading daily physical activity and exercise levels will aim at reducing weight (i.e. together with a change in diet we aim at a caloric deficit of 500 to 700 kcal/day) and improving pain cognitions at the same time.

Study design:

Randomized controlled trial with follow-up assessments directly post-treatment (T1), 3 months post-treatment (T2), 6 months post-treatment (T3), 9 months post-treatment (T4) and 12 months post-treatment (T5).

03

Conditions studied

  • Overweight or Obesity
  • Chronic Low-back Pain

Browse trials for

04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 252 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Vrije Universiteit Brussel is the lead sponsor of 160 studies on the registry; 43 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (18 - 65 years)
  • Overweight ( ≥ 25 kg/m2) or obese (BMI ≥ 30 kg/m2) women and men.
  • CLBP (n=252), which is defined as nonspecific low back pain for at least 3 months duration, currently seeking care for low back pain and leg pain not ≥ 7 (on a maximum of 10) on a numeric rating scale.
  • Continue usual care 6 weeks prior to (to obtain a steady stat) and during study participation.
  • Depending on the country of inclusion: Native Dutch speaker (for Belgium) or Native German speaker (for Switzerland).

Exclusion criteria

Exclusion Criteria:

  • Patients with ≥ 40 kg/m² will be excluded as people being morbid obese are eligible to undergo abdominal surgery. Because BMI may not always correspond to the same body fat percentage in different individuals (e.g., athletic types with higher muscle mass may also have BMIs ≥ 25 km/kg²), each participant's body fat percentage will be measured using the TANITA and compared to the body fat percentage reference values. Participants with exceeding BMI but falling into the healthy fat percentage range (which is sex-, age- and ethnicity dependent will be excluded.
  • Pregnant, currently breastfeeding or given birth in preceding year.
  • Currently receiving dietary or exercise interventions or received in the past 6 weeks.
  • Show evidence of specific spinal pathology based on self-report (e.g., hernia, spi-nal stenosis, spondylolisthesis, infection, spinal fracture or ), or a se-vere underlying comorbidity specific diagnoses that interfere with treatment (e.g., diagnosed diabetes, cardiovascular problems, metabolic diseases)
  • Other severe diseases based on current medication intake or being currently treated by a medical doctor for a specific diagnosis, (e.g. diagnosed eating disorders).
  • Ongoing problems or cases with insurance companies regarding their back.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
252 participants (estimated)

Study arms

  • Experimental
    Experimental Intervention

    Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.

    Behavioral: Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.

  • Active comparator
    Control Intervention

    Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.

    Behavioral: Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.

Interventions

  • BehavioralPhysiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.

    14 weeks, 18 treatment sessions This includes: * 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms. * 15 sessions which will focus simultaneously on cognition-targeted exercise therapy and behavioral weight reduction. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful. The behavioral weight reduction program includes a lifestyle approach, with changes in diet, behavior, and a physical exercise weight loss program, all aiming for a caloric deficit of 500 to 700 kcal/day.

    Also known as: EXP (Experimental intervention)

  • BehavioralPhysiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.

    14 weeks, 18 treatment sessions This includes: * 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms. * 15 sessions which will only focus on cognition-targeted exercise therapy. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful.

    Also known as: CON (Control intervention)

07

What researchers measure

Primary outcomes

  1. Brief Pain Inventory - Average pain Intensity

    Since CLBP is a fluctuating condition, the question "please rate your pain by circling the one number that best describes your pain on the AVERAGE" is used as primary outcome measure to evaluate pain intensity. The answer to this question is formulated on an 11-point (i.e., 0-10, a decrease of 30% is considered as clinically significant) numeric rating scale (NRS). Higher scores indicate higher pain intensity.

    Time frame: Change from baseline to 12 months post-intervention

Secondary outcomes

  1. Brief Pain Inventory - Pain intensity (Average, worst, least, now)

    The BPI will also be used to assess pain intensity at other timepoints.

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment and 12 months past-treatment

  2. Brief Pain Inventory - Pain interference on functioning

    The BPI also evaluates the impact of pain on functioning. The BPI measures how much pain interferes with seven daily activities, including general activity, walking, work, mood, enjoyment of life, relations with others, and sleep on an 11-point NRS (ranging from 0-10). Higher scores indicate a bigger interference of pain with activities of daily life.

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment and 12 months past-treatment

  3. Pain distribution and pain extent by pain drawings

    Extent of pain will be indicated by the participants making use of a digital pain drawing obtained using a digital tablet and commercially available sketching software

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment

  4. Tampa Scale for Kinesiophobia (TSK)

    The TSK contains questions about pain-related fear of movement, fear of (re)injury and fear avoidance behavior. The TSK results in a score ranging from 17 to 68, where higher scores indicate an increasing degree of kinesiophobia.

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment and 12 months past-treatment

  5. Fear Avoidance Belief Questionnaire

    The fear avoidance belief questionnaire focuses on LBP patient's beliefs about how physical activity and work affect LBP (fear of pain caused by physical activity). This questionnaire results in a total score (ranging from 0 to 96) and two subscale scores: work subscale (ranges from 0 to 42) and physical activity subscale (score 0 to 24). Higher scores indicate more strongly held fear avoidance beliefs.

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment and 12 months past-treatment

  6. Body weight - Tanita

    Body weight (kg) will be measured using TANITA MC-780SMA Bio-electrical Impedance Analyzer.

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment

  7. BMI - Tanita

    BMI will be measured using TANITA MC-780SMA Bio-electrical Impedance Analyzer.

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment

  8. Fat mass - Tanita

    Fat mass will be measured using TANITA MC-780SMA Bio-electrical Impedance Analyzer.

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment

  9. Fat free mass - Tanita

    Fat free mass will be measured using TANITA MC-780SMA Bio-electrical Impedance Analyzer.

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment

  10. Muscle mass - Tanita

    Muscle mass will be measured using TANITA MC-780SMA Bio-electrical Impedance Analyzer.

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment

  11. Body Water - Tanita

    Body water will be measured using TANITA MC-780SMA Bio-electrical Impedance Analyzer.

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment

  12. Waist-hip circumference

    Measured using a Cescorf measuring tape,

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment

  13. Regional body composition - portable ultrasound scanner

    Subcutaneous adipose tissue thickness of the triceps, biceps, subscapular, iliac crest, supraspinal, abdominal and medial calf will be assessed. Additionally, muscle thickness of the multifidi will be assessed.

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment

  14. Accelerometry Fitbit

    To objectively measure sedentary behavior, physical activity and sleep quantity/quality

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment

  15. Sleep Quality - Pittsburg Sleep Quality Index

    Questionnaire assessing Sleep Quality. In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality.

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment and 12 months past-treatment

  16. Dietary Intake

    a 3 day food diary, 2 week days and 1 weekend day, will be used to analyse their dietary intake.

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment and 12 months past-treatment

  17. Health Economics - Medical Consumption Questionnaire

    a generic instrument for measuring patient's total direct and indirect medical consumption. For this type of questionnaire and the aspect it is measuring, we cannot refer to minimum or maximum values.

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment, 9 months post-treatment and 12 months past-treatment

  18. Health Economics - Productivity Cost Questionnaire

    to obtain data regarding the indirect medical costs (e.g., the costs due to absenteeism or presenteeism). For this type of questionnaire and the aspect it is measuring, we cannot refer to minimum or maximum values.

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment, 9 months post-treatment and 12 months past-treatment

  19. Health Economics - EuroQol EQ-5D-5L

    to assess health profiles which will be transformed into utilities using the Flemish or German Tariffs respectively. For this type of questionnaire and the aspect it is measuring, we cannot refer to minimum or maximum values.

    Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment, 9 months post-treatment and 12 months past-treatment

08

Study locations

2 of 2 sites recruiting
  • Vrije Universiteit Brussel
    Brussels, 1090, Belgium
    Recruiting
  • Berner Fachhochschule
    Bern, 3012, Switzerland
    Recruiting
    • Heiner Baur · Contactheiner.baur@bfh.ch
    • Melanie Liechti, MSc · Contactmelanie.liechti@bfh.ch
    • Jan Taeymans, PhD · Principal investigator
    • Ron Clijsen, PhD · Sub investigator
    • Melanie Liechti, MSc · Sub investigator
    • Alexander Schurz, MSc · Sub investigator
09

References and documents

Publications

  • Schurz AP, Lutz N, Liechti M, Malfliet A, Vanroose M, Maebe Z, Nijs J, Van Bogaert W, Clarys P, Clijsen R, Baur H, Taeymans J, Deliens T. Cost of illness analysis in individuals with overweight or obesity and chronic low back pain in the Bern metropolitan area (the BO2WL trial). Front Public Health. 2026 Jan 13;13:1705891. doi: 10.3389/fpubh.2025.1705891. eCollection 2025. PubMed 41607914 ↗
  • Schurz AP, Deliens T, Liechti M, Vanroose M, Clijsen R, Nijs J, Malfliet A, Van Bogaert W, Clarys P, Baur H, Taeymans J, Lutz N. Economic evaluation of a lifestyle intervention for individuals with overweight or obesity suffering from chronic low back pain (the BO2WL trial): a protocol for a health economic analysis. BMJ Open. 2025 Jun 20;15(6):e098272. doi: 10.1136/bmjopen-2024-098272. PubMed 40541436 ↗

Individual participant data

Plan to share: No — We do not plan to share any IPD

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Apr 2028, 60 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 60 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2023
First posted
Apr 13, 2023
StartActual
Apr 13, 2023
Primary completionEst.
Apr 2028
CompletionEst.
Nov 2028
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05811624
Collaborators
Bern University of Applied Sciences, University of Applied Sciences and Arts of Southern Switzerland
Responsible party
Jo Nijs (Full professor, Vrije Universiteit Brussel) — Principal investigator
First posted
Apr 13, 2023
Start date
Apr 13, 2023
Primary completion
Apr 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Aug 20, 2026

Study contacts

Anneleen Malfliet, PhD
Contact
anneleen.malfliet@vub.be
003224774531
Jo Nijs, PhD
Contact
jo.nijs@vub.be
Jo Nijs, PhD
principal investigator · Vrije Universiteit Brussel

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion